Table 1 Characteristics of the study subjects in the Polish cohort.
asthma, N = 326 | controls, N = 111 | |
|---|---|---|
age, years* | 59.2 ± 15.9 (18–94) | 52.3 ± 18.3 (24–81) |
gender, women, n (%) | 201 (61.7%) | 72 (64.9%) |
Men > 50 yr average age (range)/n | 67.3 ± 9.8 (50–87)/92 | 65.2 ± 9.7 (50–80)/18 |
Men < 50 yr average age (range)/n | 34.2 ± 7.5 (18–48)/33 | 32.9 ± 5.9 (24–48)/21 |
Women > 50 yr average age (range)/n | 67.3 ± 9.3 (50–94)/144 | 67 ± 7.2 (51–81)/47 |
Women < 50 yr average age (range)/n* | 40 ± 6.6 (24–49)/57 | 34.1 ± 6.5 (26–49)/25 |
Atopy, n/N tested (%)* | 141/273 (51.6%) | 39/111 (35.1%) |
FEV1% pred. | 75.3 ± 24.1 (17.5–129.5) | – |
FEV1%/FVC | 68 ± 13.1 (25.6–99.4) | – |
ACT, points | 17.8 ± 5.5(4–25) | – |
FeNO (ppb) | 30.6 ± 17.8 (2–184) | – |
Asthma control (according to GINA 2016) | ||
Controlled, n (%) | 72 (22%) | – |
partly controlled, n (%) | 96 (30%) | – |
Uncontrolled, n (%) | 156 (48%) | – |
Current asthma treatment | ||
ICS, n (%) | 240 (73.6%) | – |
low dose**, n (%) | 28 (8.6%) | |
medium dose**, n (%) | 120 (36.8%) | |
high dose dose**, n (%) | 92 (28.2%) | |
Oral steroids, n (%) | 23 (7.1%) | – |
LABA, n (%) | 197 (60.4%) | |
Leukotriene antagonists, n (%) | 64 (19.6%) | |
at least 1 exacerbation/last year, n (%) | 170 (52.1%) | – |
